TICKERNERD
Menu
TLRYTLRYHealthcare · Drug Manufacturers - Specialty & Generic

TLRY Stock Forecast: Tilray Brands, Inc. Price Predictions for 2026-2027

Last close, 7 Aug 2026
$4.57
+2.93% on the day

The 10 Wall Street analysts covering Tilray Brands, Inc. hold a median 12-month price target of $5.75 — +25.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 18 of 100 as at 7 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$602.7M
Ticker Nerd rank
18 / 100
Median analyst target
$5.75
Analysts covering
10
Total return, dividends reinvested
1W
+0.7%
1M
+6.0%
YTD
−49.4%
1Y
−29.7%
From 52W high
−78.2%
From 52W low
+17.8%
$4
$21
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

TLRY stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Tilray Brands, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 7 Aug 2026
18 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
94
Size
51
Revisions
37
Accruals
31
Quality
29
Value
24
Momentum
22
Issuance
15
Volatility
14

Growth (94): Sales and profits are climbing, and climbing faster than before.

Volatility (14): The share price moves around a lot.

The rank is the raw material. Whether the rules would actually own Tilray Brands, Inc. — and when they’d sell — is the membership.

Wall Street

TLRY stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TLRY, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5$10$15$20Oct 25Jan 26Apr 26Jul 26TLRYHigh $19.00Median $5.75Low $4.25

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says10 analysts
3 Buy7 Hold0 Sell
Low $4.25Median $5.75High $19.00

The green dot is the last close — the median target sits +25.8% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
14 July 2026TD CowenMaintainsBuy$7.00 → $5.00
2 Apr 2026Roth CapitalUpgradeBuy—
30 Mar 2026TD CowenMaintainsBuy—
20 Jan 2026Roth CapitalMaintainsNeutral—
25 Aug 2025JefferiesMaintainsBuy—
29 July 2025Zelman & AssocReiteratesNeutral—
9 Apr 2025Piper SandlerMaintainsNeutral—
11 Oct 2024Roth MKMMaintainsNeutral—
27 June 2024Zuanic & AssociatesInitiatesNeutral—
10 Apr 2024CIBCMaintainsNeutral—
1 Sept 2023Roth MKMReiteratesNeutral—
11 Apr 2023TD CowenMaintainsOutperform—
10 Jan 2023Alliance Global PartnersMaintainsNeutral—
2 Nov 2022BernsteinInitiatesMarket Perform—
10 Oct 2022Cantor FitzgeraldMaintainsNeutral—
30 Sept 2022BarclaysMaintainsUnderweight—
2 Aug 2022Cantor FitzgeraldMaintainsNeutral—
29 July 2022BenchmarkDowngradeSell—
15 July 2022Roth CapitalMaintainsNeutral—
24 June 2022Cantor FitzgeraldMaintainsNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

TLRY analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−4.1%
Analysts raising
1
Analysts cutting
0
Fundamentals

Tilray Brands, Inc. (TLRY) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−4.1×

Cheaper than 88% of US stocks

Price / sales
0.7×

Cheaper than 78% of US stocks

Price / book
1.5×

Cheaper than 57% of US stocks

EV / EBITDA
126.5×

Cheaper than 2% of US stocks

Growth & margins
Revenue growth (YoY)
−7.8%

Higher than 17% of US stocks

Earnings growth (YoY)
25.5%

Higher than 65% of US stocks

Gross margin
32.1%

Higher than 39% of US stocks

Operating margin
−52.7%

Higher than 17% of US stocks

Net margin
−13.3%

Higher than 18% of US stocks

Returns & dividend
Return on equity
−6.8%

Higher than 38% of US stocks

Return on assets
−1.5%

Higher than 38% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

TLRY vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
TLRYTilray Brands, Inc.$602.7M
18
IRWDIronwood Pharmaceuticals, Inc.$704.4M
100
BIOABioAge Labs, Inc.$520.1M
43
EOLSEvolus, Inc.$493.8M
84
GLASGlass House Brands, Inc.$793.1M
65
AQSTAquestive Therapeutics, Inc.$476.6M
57
CGCCanopy Growth Corp.$438.3M
45
Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TLRY appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

News

Latest TLRY news & analysis

3 Top Canadian Marijuana Stock Picks To Add Value To Your Portfolio

MarijuanaStocks · 5 Aug 2026neutral

An article from MarijuanaStocks discusses the divide between large cannabis companies like Tilray and smaller operators, noting that as legal cannabis grows, bigger firms are typically better positioned to win in the long run. The piece suggests investors are focused on companies showing profitability and a path toward innovation.

Why it matters — TLRY watchers would care because the article positions Tilray among the big cannabis companies that could benefit as market consolidation continues.

The Surprising Part of Tilray's Business That Drove Most of Its Growth Last Year

The Motley Fool · 3 Aug 2026positive

Tilray's revenue rose 11% in fiscal year 2026, led by its distribution business, which grew 21% and was the company's strongest segment, according to The Motley Fool.

Why it matters — The report highlights that distribution, not cannabis, drove most of Tilray's growth, offering watchers insight into which part of the business is fuelling revenue.

Tilray Brands seen creating long-term value through diversified platform, Jefferies says

Proactive Investors · 30 July 2026neutral

Jefferies reiterated its 'Buy' rating on Tilray Brands while lowering its price target to $19 and cutting earnings forecasts, after management guided to fiscal 2027 adjusted EBITDA of $68 million to $75 million, below the consensus estimate of $84 million. Shares traded up nearly 3% on the day.

Why it matters — The analyst's long-term positive outlook and the company's guidance falling short of consensus are both significant inputs for investors tracking Tilray's shifting strategy and financial trajectory.

Tilray Brands stock continues its downward spiral: buy the dip or sell the rip?

Invezz · 30 July 2026negative

Tilray Brands stock continued its strong downtrend, falling to its lowest level since June last year. TLRY has dropped 57% this year, in line with other cannabis stocks like Green Thumb Industries, Truelive Cannabis, and Curaleaf.

Why it matters — TLRY watchers would care because the stock continues to decline sharply, mirroring a broader downturn across the cannabis sector.

FAQ

Frequently asked questions about TLRY stock

What is the TLRY stock price forecast for 2026-2027?

The 10 Wall Street analysts covering Tilray Brands, Inc. have a median 12-month price target of $5.75, with estimates ranging from $4.25 to $19. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is TLRY stock a buy right now?

Of the 10 analysts covering Tilray Brands, Inc., 3 rate it a Buy, 7 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Tilray Brands, Inc. 18 out of 100 across roughly 4,600 US stocks as at 7 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank TLRY?

As at 7 Aug 2026, Tilray Brands, Inc. ranks 18 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (94 of 100).

Will TLRY stock go up?

No one can know that. What the data says: the median 12-month target from 10 analysts implies +25.8% from the last close, and Ticker Nerd's factor model ranks Tilray Brands, Inc. 18 out of 100 as at 7 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the TLRY stock forecast for 2030?

No analyst covering Tilray Brands, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TLRY are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4.25 to $19 over the next 12 months.

How has TLRY stock performed over the past year?

Tilray Brands, Inc. returned -29.7% over the 12 months to 7 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Tilray Brands, Inc. do?

Tilray Brands, Inc. is a lifestyle consumer packaged goods company focused on cannabis and adjacent categories.

What is the latest news on TLRY?

The most recent item we track (MarijuanaStocks, 5 Aug 2026): "3 Top Canadian Marijuana Stock Picks To Add Value To Your Portfolio". An article from MarijuanaStocks discusses the divide between large cannabis companies like Tilray and smaller operators, noting that as legal cannabis grows, bigger firms are typically better positioned to win in the long run. The piece suggests investors are focused on companies showing profitability and a path toward innovation.

Company

About Tilray Brands, Inc.

Tilray Brands, Inc. is a lifestyle consumer packaged goods company focused on cannabis and adjacent categories. The company engages in the research, cultivation, processing, and distribution of medical and adult-use cannabis products across Canada, the United States, Europe, the Middle East, Africa, and other international markets. Its operations are organized into four main segments: Cannabis, Beverage, Distribution, and Wellness. Within these segments, Tilray Brands offers branded medical and recreational cannabis, resells and distributes pharmaceutical and wellness products, and produces beverage alcohol, including beer and spirits, as well as hemp-based food products. The company markets its portfolio through a wide range of established brands spanning cannabis, craft brewing, spirits, and wellness-focused consumer products. Headquartered in Leamington, Canada, and founded in 2018, Tilray Brands, Inc. plays a notable role in the global cannabis and consumer packaged goods landscape by supplying products to medical patients, adult-use consumers, and retail and wholesale partners in multiple regions.

CEO Mr. Irwin David Simon · 3,595 employees · Canada · https://www.tilray.com